Other Information
−Removed: During the three months ended June 29, 2024, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows:
−Removed: Trading Arrangement
−Removed: Name and Title Action Date (1)
−Removed: Rule 10b5-1* Non-Rule 10b5-1** Number of Shares to be Sold (2)
−Removed: Expiration Date (3)
−Removed: Llorens , EVP, Global Manufacturing and Supply Chain
−Removed: Adoption 6/12/2024 X 14,314
−Removed: * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
−Removed: ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
−Removed: (1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director.
−Removed: (2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable.
−Removed: (3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above.
+Added: During the three months ended September 28, 2024, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.
Restated Articles of Organization of the Company, reflecting Articles of Amendment dated August 23, 1993, August 21, 2006, July 26, 2018 and July 25, 2019 (filed as Exhibit 3.1 to the Company’s Form 8-K dated July 29, 2019 and incorporated herein by reference).
By-Laws of the Company, as amended through June 29, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K dated June 30, 2020 and incorporated herein by reference).
−Removed: Indenture, dated as of May 28, 2024, between Haemonetics Corporation and U.S.
−Removed: Bank National Association, as trustee.
−Removed: (filed as Exhibit 4.1 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
−Removed: Form of certificate representing the 2.50% Convertible Senior Notes due 2029 (included as Exhibit A to Exhibit 4.1) (filed as Exhibit 4.2 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
−Removed: Second Amended and Restated Credit Agreement, dated as of April 30, 2024, by and among the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (filed as Exhibit 10.1 to the Company’s Form 8-K dated May 1, 2024 and incorporated herein by reference).
−Removed: Form of Confirmation of Base Call Option Transaction (filed as Exhibit 10.1 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
−Removed: Form of Confirmation of Additional Call Option Transaction (filed as Exhibit 10.2 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A.
6 unchanged sentences
D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
−Removed: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended June 29, 2024 formatted in inline Extensible Business Reporting Language (XBRL) includes:
+Added: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended September 28, 2024 formatted in inline Extensible Business Reporting Language (XBRL) includes:
(i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statement of Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
4 unchanged sentences
HAEMONETICS CORPORATION
−Removed: August 8, 2024 By:
+Added: November 7, 2024 By:
/s/ Christopher A.
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 8, 2024 By:
+Added: November 7, 2024 By:
D’Arecca, Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.